WTR Fireside Chat Series: Theratechnologies President & CEO Paul Lévesque and Chief Medical Officer Christian Marsolais, on Wednesday at February 10th at 2:00 pm EST (11 am PST) – Replay Now Available
We will be hosting CEO Paul Lévesque and CMO Christian Marsolais in our Water Tower Research Fireside Chat Series on Wednesday, February 10th at 2:00 pm EST. The event is open to all investors.
The discussion will focus on the FDA fast-track designation received by the company for its lead peptide-drug conjugate TH1902, which uses the company’s proprietary SORT1+ Technology.
SORT1+ Technology targets sortilin 1 receptor positive cancers by linking oncology drugs such as docetaxel to a proprietary peptide that binds to the receptor. This less toxic, targeted therapy can potentially be used for such cancers as colorectal, pancreatic, ovarian, and triple negative breast cancer.Register for this Event HERE